[
    [
        {
            "time": "",
            "original_text": "百济神州“穿绿鞋”仍下跌，高瓴持股11%没有限售期",
            "features": {
                "keywords": [
                    "百济神州",
                    "绿鞋机制",
                    "下跌",
                    "高瓴资本",
                    "持股比例",
                    "限售期"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "百济神州“穿绿鞋”仍下跌，高瓴持股11%没有限售期",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "华软科技：为凯莱英提供小分子新药项目的重要中间体",
            "features": {
                "keywords": [
                    "华软科技",
                    "凯莱英",
                    "小分子新药",
                    "中间体"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药制造"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "华软科技：为凯莱英提供小分子新药项目的重要中间体",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "中药股价暴涨，哪些标的适合机构配置？【东吴医药朱国广团队】",
            "features": {
                "keywords": [
                    "中药",
                    "暴涨",
                    "机构配置",
                    "东吴医药",
                    "朱国广团队"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "中医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "中药股价暴涨，哪些标的适合机构配置？【东吴医药朱国广团队】",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]